



(12) Translation of
European patent specification

(11) NO/EP 3897636 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/445 (2006.01)

C07D 241/04 (2006.01)

A61K 31/497 (2006.01)

C07D 401/14 (2006.01)

A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2025.04.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.12.11
(86)	European Application Nr.	19901383.0
(86)	European Filing Date	2019.12.18
(87)	The European Application's Publication Date	2021.10.27
(30)	Priority	2018.12.19, US, 201862782298 P 2019.07.29, US, 201962879900 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Celgene Corporation, Route 206 & Province Line Road, Princeton, NJ 08543, USA
(72)	Inventor	AMMIRANTE, Massimo, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA BAHMANYAR, Sogoie, PO Box 3693, Rancho Santa Fe, CA 92067, USA CORREA, Matthew, D., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA GRANT, Virginia, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA HANSEN, Joshua, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA HORN, Evan, J., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA KERCHER, Timothy, S., 1829 Caleta Trail, Longmont, CO 80504, USA MAYNE, Christopher, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA NAGY, Mark, A., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA NARLA, Rama, Krishna, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA NAYAK, Surendra, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA NORRIS, Stephen, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA PAPA, Patrick, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA PLANTEVIN-KRENITSKY, Veronique, 301 Christopher Dr., San Francisco, CA 94131, USA SAPIENZA, John, J., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA WHITEFIELD, Brandon, W., 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA SU, Shuichan, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
(56)	References Cited:	EP-A1- 2 894 151 US-A1- 2018 179 164 US-A1- 2016 096 818 US-A1- 2008 064 876 EP-A1- 3 897 635 US-A1- 2018 008 587 WO-A1-2017/123542 US-A1- 2013 116 269

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav**1.** En forbindelse valgt fra gruppen som består av:

- 5 (S)-2-(4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid;
- 2-((S)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-3-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid;
- 10 2-((R)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid;
- 2-((S)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-N-(3-
- 15 (2,6-dioksopiperidin-3-ylamino)fenyl)acetamid; and
- N-(3-klor-5-(2,6-dioksopiperidin-3-ylamino)fenyl)-2-((R)-4-(2-(4-(3-(6-cyano-5-(trifluormetyl)pyridin-3-yl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-
- 20 acetamid;
- eller et farmasøytisk akseptabelt salt derav.

2. Forbindelsen ifølge krav 1 valgt fra gruppen som består av:

- 25 (S)-2-(4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid;
- 2-((S)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-3-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid;
- 30 2-((R)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid;

2-((S)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid; and
 N-(3-klor-5-(2,6-dioksopiperidin-3-ylamino)fenyl)-2-((R)-4-(2-(4-(3-(6-cyano-5-(trifluormetyl)pyridin-3-yl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-acetamid.

3. Forbindelsen ifølge krav 1 eller 2 som er (S)-2-(4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid.

4. Forbindelsen ifølge krav 1 eller 2 som er 2-((S)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-3-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid.

5. Forbindelsen ifølge krav 1 eller 2 som er 2-((R)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid.

6. Forbindelsen ifølge krav 1 eller 2 som er 2-((S)-4-(2-(4-(3-(4-cyano-3-(trifluormetyl)fenyl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)-N-(3-(2,6-dioksopiperidin-3-ylamino)fenyl)acetamid.

7. Forbindelsen ifølge krav 1 eller krav 2 som er N-(3-klor-5-(2,6-dioksopiperidin-3-ylamino)fenyl)-2-((R)-4-(2-(4-(3-(6-cyano-5-(trifluormetyl)pyridin-3-yl)-5,5-dimetyl-4-okso-2-tioksoimidazolidin-1-yl)-2-etylfenoksy)etyl)-2-metyl piperazin-1-yl)acetamid.

8. En farmasøytisk sammensetning som omfatter en effektiv mengde av en forbindelse ifølge hvilket som helst foregående krav, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel bærer, eksipiens eller vehikkel.

5

9. Den farmasøytiske sammensetningen i henhold til krav 8, som omfatter en effektiv mengde av en forbindelse ifølge hvilket som helst foregående krav, og en farmasøytisk akseptabel bærer, eksipiens eller vehikkel.

10 **10.** Forbindelsen ifølge hvilket som helst av krav 1 til 7 for anvendelse i en fremgangsmåte for behandlingen av en androgenreseptormedierte sykdom, hvor den androgenreseptormedierede sykdommen er prostatakraft.

15 **11.** Den farmasøytiske sammensetningen ifølge hvilket som helst av krav 8 eller 9 for anvendelse i en fremgangsmåte for behandlingen av en androgenreseptormedierte sykdom, hvor den androgenreseptormedierede sykdommen er prostatakraft.

20 **12.** Forbindelsen for anvendelse ifølge krav 10, hvor prostatakraften er kastrasjonsresistent prostatakraft (CRPC).

13. Den farmasøytiske sammensetningen for anvendelse i henhold til krav 11, hvor prostatakraften er kastrasjonsresistent prostatakraft (CRPC).